Progress Update: Prostate Cancer Imaging and Treatment

Course overview

UAN: 0018-0000-17-207-H04-P RELEASE: 10/16/2017 EXPIRE: 10/16/2020 CREDITS: 2.5 LEARNING OBJECTIVES: 1. Describe the importance of PMSA as a potential imaging agent 2. Review example cases showing the role of Ga-68 PMSA in detecting prostate cancer 3. Identify potential next steps for using PSMA PET imaging in patients with prostate cancer 4. Review methods for initially diagnosising prostate cancer as well as current treatment options 5. Define and describe biochemically recurrent prostate cancer 6. Compare current methods for the detection and localization of biochemical recurrent prostate cancer 7. Review the currently approved PET imaging agents for BCR prostate cancer 8. Summarize current approaches for prostate cancer treatment 9. Describe the current role of providing bone pain palliation with beta emitting radioisotopes 10. Illustrate the role that alpha emitting radioisotopes can play in improving patient survival NOTE: An annual subscription for Purdue’s nuclear pharmacy recertification program provides access to both the continuing education component of the program and the Radiopharmacy Portal, a reference resource for practitioners. Subscriptions to the continuing educational offerings, which have been accredited through ACPE and BPS, can be purchased for an annual fee of $195 for nuclear pharmacists and $95 for nuclear pharmacy technicians.